Achieve Life Sciences (ACHV) Restructuring Costs (2016)

Achieve Life Sciences (ACHV) posted Restructuring Costs of -$431000.0 for Q3 2016, down 131.35% on a QoQ basis from $1.4 million in Q2 2016.

Achieve Life Sciences (ACHV) Restructuring Costs (2016) Analysis & Trends

Achieve Life Sciences' Restructuring Costs history runs 1 years deep, the most recent figure standing at -$431000.0 for Q3 2016.

Quarterly Restructuring Costs changed N/A year-over-year to -$431000.0 in Q3 2016, while the trailing twelve-month figure through Dec 2016 was $1.4 million (changed N/A YoY) and the FY2016 annual result came in at $1.4 million, changed N/A from the prior year.
Restructuring Costs was -$431000.0 for Q3 2016 at Achieve Life Sciences, down from $1.4 million in the prior quarter.
Across five years, Restructuring Costs topped out at $1.4 million in Q2 2016 and bottomed at -$431000.0 in Q3 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Achieve Life Sciences	326.16 Mn	326.16 Mn	-

Download Data